<DOC>
	<DOCNO>NCT02509767</DOCNO>
	<brief_summary>This randomize clinical trial study subcutaneous depot medroxyprogesterone acetate ( DMPA sc ) self-administration two Planned Parenthood affiliate serve diverse patient population . Prior study demonstrate DMPA self-injection safe , effective , feasible , acceptable woman adolescent . A total 400 female patient ( age 15-44 ) request DMPA randomize self-administration DMPA sc clinic administration ( usual care ) . Subjects follow one year . The primary study outcome DMPA continuation one year self-report study arm . Secondary outcome include patient-reported satisfaction treatment ; satisfaction home use ; cost associate contraceptive care . The investigator hypothesize high continuation rate among self-injection user compare patient receive standard care . Secondary exploratory hypothesis include high patient satisfaction lower cost associate contraceptive care among self-injection user .</brief_summary>
	<brief_title>Depo Provera Self-Administration Study : Putting Patient-Centered Practice Test Planned Parenthood</brief_title>
	<detailed_description>This open-label , randomized parallel group clinical trial study subcutaneous depot medroxyprogesterone acetate ( DMPA sc ) self-administration two Planned Parenthood affiliate serve diverse patient population . Prior study demonstrate DMPA self-injection safe , effective , feasible , acceptable woman adolescent . A total 400 female patient ( age 15-44 ) request DMPA randomize self-administration DMPA sc clinic administration ( usual care ) 1:1 allocation . Subjects follow one year . All subject receive reminder next injection due . Follow-up survey conduct 6 12 month . Adherence monitor subject self-report study outcome ascertain self-report medical record review . The primary study outcome DMPA continuation one year self-report study arm . Secondary outcome include patient-reported satisfaction treatment ; satisfaction home use ; cost associate contraceptive care . The investigator hypothesize high continuation rate among self-injection user compare patient receive standard care ( delta = .13 ; 80 % power ; one-sided α=0.05 ; allow 15 % loss-to-follow-up ) . Secondary exploratory hypothesis include high patient satisfaction lower cost associate contraceptive care among self-injection user .</detailed_description>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<criteria>Females age 1544 Current past user DMPA desire initiation DMPA contraception Can understand speak write English Spanish Willing consider/attempt DMPA selfinjection Willing randomize either self clinic administration DMPA Do want become pregnant next 12 month Willing provide contact information complete three survey baseline , 6 month , 12 month Have consistent access work telephone , email , Internet No contraindication DMPA use Suspected confirm pregnancy Vaginal bleeding unknown etiology Known suspect breast cancer Acute liver disease High blood pressure ( Systolic ≥ 160 mm Hg diastolic ≥ 100 mm Hg ) Known hypersensitivity medroxyprogesterone acetate component DMPA Desire pregnancy within one year</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Contraceptive Methods</keyword>
	<keyword>Female Contraception</keyword>
	<keyword>Contraceptive satisfaction</keyword>
	<keyword>Injectable contraception</keyword>
	<keyword>Birth control</keyword>
</DOC>